ETV6 and chronic myelogenous leukemia, BCR-ABL1 positive: This approach has been exploited in various entities, such as ALL with t(12;21)/ETV6::RUNX1426,43, ALL with 11q23/KMT2A aberrations446,45, ALL or CML with t(9;22)/BCR::ABL1416,46,47 and other hematopoietic malignancies48–50.